Pillar VC — 2024 Investments
5 investments dated 2024 · listed companies and verified rows first · show all
Adaptilens develops a biomimetic accommodating intraocular lens (A-IOL) for cataract and vision correction, an ophthalmic medical device.
BiotechHardwareHealthtechMedical DevicesChestnut Hill, US
Liane Clamen(Inventor / Founder)in
BoardJohn Andres(Director)Terry Kim(Director)William Shea(Director)Robert Doris(Director)
Board seatJamie Goldstein· per SEC Form D
Amplifyer develops liquid biopsy technology aimed at improving outcomes for cancer patients.
BiotechHealthtechMedical DevicesLexington, US
Annie MurphyinEric K. Huang(Executive Officer, Director)J. Christopher Love(Director)Viktor A. Adalsteinsson(Director)
BoardThomas de Vlaam(Director)inStanley Lapidus(Director)in
Higharc provides construction operations management software for homebuilders, offering a single source of truth for plan portfolio management including plans, elevations, options, standards, pricing and sales availability across communities.
AI & Machine LearningConstruction TechPropTechSaaS
Marc Minor(Founder)inMichael Bergin(Founder)inPeter Boyer(Founder)inThomas Holt(Founder)in
Co-investorsFifth WallFounder CollectiveInsight PartnersJavelin Venture PartnersLux CapitalMetaProp+16 more
Odysee builds AI-powered software for airline schedule planning, offering data-driven tradeoff analysis, stress-test simulation, and automated schedule recommendations.
AI & Machine LearningMobility & TransportationSaaS
Julian Chandra(Founder)in
Co-investorsUP Partners
Rowan offers a web app and Python API for molecular design, simulation, and property prediction, including workflows for pKa, bond strength, redox potentials, protein-ligand binding affinity, and ADME properties.
AI & Machine LearningBiotechSaaSAllston, US
Arien Wagen(Executive Officer, Director)Corin Wagen(Executive Officer, Director)in
Co-investorsAI Grant
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
















